Head-to-head comparison of 64Cu-DOTATATE and 68Ga -DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors

Research output: Contribution to journalJournal article – Annual report year: 2016Researchpeer-review

Standard

Head-to-head comparison of 64Cu-DOTATATE and 68Ga -DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. / Johnbeck, C.B.; Knigge, U.; Loft, A.; Bertelsen, A.K.; Mortensen, J.; Oturai, P.; Langer, S.; Elema, Dennis Ringkjøbing; Kjaer, A.

In: The Journal of Nuclear Medicine, Vol. 58, No. 3, 2016, p. 451-457.

Research output: Contribution to journalJournal article – Annual report year: 2016Researchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Johnbeck, C.B. ; Knigge, U. ; Loft, A. ; Bertelsen, A.K. ; Mortensen, J. ; Oturai, P. ; Langer, S. ; Elema, Dennis Ringkjøbing ; Kjaer, A. / Head-to-head comparison of 64Cu-DOTATATE and 68Ga -DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. In: The Journal of Nuclear Medicine. 2016 ; Vol. 58, No. 3. pp. 451-457.

Bibtex

@article{bcf7da08b54d4d0695a8d92624579fdc,
title = "Head-to-head comparison of 64Cu-DOTATATE and 68Ga -DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors",
abstract = "Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up and treatment planning of neuroendocrine tumor (NET) patients. Positron emission tomography (PET) based tracers using 68Ga as the radioisotope have in most centers replaced single-photon emission tomography (SPECT) based tracers as the gold standard. 64Cu-DOTATATE is a new PET tracer that has been shown to be far superior compared to the SPECT tracer 111In-DTPA-octreotide. Due to advantages of 64Cu compared to 68Ga, we hypothesize that the tracer could have a higher sensitivity than 68Ga-based tracers. To test this hypothesis, we compared on a head-to-head basis the diagnostic performance of 64Cu-DOTATATE with that of 68Ga -DOTATOC in NET patients. Objectives 64Cu-DOTATATE is a new PET tracer for somatostatin receptor imaging. 64Cu-DOTATATE may potentially have a higher sensitivity than the current gold standards, due to advantages of 64Cu compared to 68Ga. The aim was to test this hypothesis on a head to head basis in neuroendocrine tumor patients (NET). Methods Fifty-nine NET patients were scanned with 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT and discordant lesions were verified through follow-up. Both scans were made within a week (1-5 days apart). Results A total of 701 lesions were concordantly detected on both 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT scans while additional 68 lesions were found by only one of the two scans. 64Cu-DOTATATE showed 42 discordant lesions of which 33 were found to be true positive on follow up. 68Ga-DOTATOC showed 26 discordant lesions, but only 7 were found to be true positive on follow up. False positives were mainly lymph node lesions. Eighty-three percent of the additional true positive lesions were found by 64Cu-DOTATATE. 64Cu-DOTATATE and 68Ga-DOTATOC discovered additional true lesions in 13 and 3 patients, respectively. All patients with additional lesions also had concordant lesions found by both scans. Conclusions Although patient based sensitivity was the same for 64Cu-DOTATATE and 68Ga-DOTATOC in this cohort, more lesions were found by 64Cu-DOTATATE. Furthermore the shelve life of more than 24 hours and a scan window of at least 3 hours make 64Cu-DOTATATE logistically attractive to use in the clinic.",
keywords = "64Cu-DOTATATE, 68Ga-DOTATOC, Neuroendocrine, Oncology, Endocrine, PET/CT, Neuroendocrine tumors, Somatostatin receptor imaging",
author = "C.B. Johnbeck and U. Knigge and A. Loft and A.K. Bertelsen and J. Mortensen and P. Oturai and S. Langer and Elema, {Dennis Ringkj{\o}bing} and A. Kjaer",
year = "2016",
doi = "10.2967/jnumed.116.180430",
language = "English",
volume = "58",
pages = "451--457",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine",
number = "3",

}

RIS

TY - JOUR

T1 - Head-to-head comparison of 64Cu-DOTATATE and 68Ga -DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors

AU - Johnbeck, C.B.

AU - Knigge, U.

AU - Loft, A.

AU - Bertelsen, A.K.

AU - Mortensen, J.

AU - Oturai, P.

AU - Langer, S.

AU - Elema, Dennis Ringkjøbing

AU - Kjaer, A.

PY - 2016

Y1 - 2016

N2 - Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up and treatment planning of neuroendocrine tumor (NET) patients. Positron emission tomography (PET) based tracers using 68Ga as the radioisotope have in most centers replaced single-photon emission tomography (SPECT) based tracers as the gold standard. 64Cu-DOTATATE is a new PET tracer that has been shown to be far superior compared to the SPECT tracer 111In-DTPA-octreotide. Due to advantages of 64Cu compared to 68Ga, we hypothesize that the tracer could have a higher sensitivity than 68Ga-based tracers. To test this hypothesis, we compared on a head-to-head basis the diagnostic performance of 64Cu-DOTATATE with that of 68Ga -DOTATOC in NET patients. Objectives 64Cu-DOTATATE is a new PET tracer for somatostatin receptor imaging. 64Cu-DOTATATE may potentially have a higher sensitivity than the current gold standards, due to advantages of 64Cu compared to 68Ga. The aim was to test this hypothesis on a head to head basis in neuroendocrine tumor patients (NET). Methods Fifty-nine NET patients were scanned with 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT and discordant lesions were verified through follow-up. Both scans were made within a week (1-5 days apart). Results A total of 701 lesions were concordantly detected on both 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT scans while additional 68 lesions were found by only one of the two scans. 64Cu-DOTATATE showed 42 discordant lesions of which 33 were found to be true positive on follow up. 68Ga-DOTATOC showed 26 discordant lesions, but only 7 were found to be true positive on follow up. False positives were mainly lymph node lesions. Eighty-three percent of the additional true positive lesions were found by 64Cu-DOTATATE. 64Cu-DOTATATE and 68Ga-DOTATOC discovered additional true lesions in 13 and 3 patients, respectively. All patients with additional lesions also had concordant lesions found by both scans. Conclusions Although patient based sensitivity was the same for 64Cu-DOTATATE and 68Ga-DOTATOC in this cohort, more lesions were found by 64Cu-DOTATATE. Furthermore the shelve life of more than 24 hours and a scan window of at least 3 hours make 64Cu-DOTATATE logistically attractive to use in the clinic.

AB - Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up and treatment planning of neuroendocrine tumor (NET) patients. Positron emission tomography (PET) based tracers using 68Ga as the radioisotope have in most centers replaced single-photon emission tomography (SPECT) based tracers as the gold standard. 64Cu-DOTATATE is a new PET tracer that has been shown to be far superior compared to the SPECT tracer 111In-DTPA-octreotide. Due to advantages of 64Cu compared to 68Ga, we hypothesize that the tracer could have a higher sensitivity than 68Ga-based tracers. To test this hypothesis, we compared on a head-to-head basis the diagnostic performance of 64Cu-DOTATATE with that of 68Ga -DOTATOC in NET patients. Objectives 64Cu-DOTATATE is a new PET tracer for somatostatin receptor imaging. 64Cu-DOTATATE may potentially have a higher sensitivity than the current gold standards, due to advantages of 64Cu compared to 68Ga. The aim was to test this hypothesis on a head to head basis in neuroendocrine tumor patients (NET). Methods Fifty-nine NET patients were scanned with 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT and discordant lesions were verified through follow-up. Both scans were made within a week (1-5 days apart). Results A total of 701 lesions were concordantly detected on both 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT scans while additional 68 lesions were found by only one of the two scans. 64Cu-DOTATATE showed 42 discordant lesions of which 33 were found to be true positive on follow up. 68Ga-DOTATOC showed 26 discordant lesions, but only 7 were found to be true positive on follow up. False positives were mainly lymph node lesions. Eighty-three percent of the additional true positive lesions were found by 64Cu-DOTATATE. 64Cu-DOTATATE and 68Ga-DOTATOC discovered additional true lesions in 13 and 3 patients, respectively. All patients with additional lesions also had concordant lesions found by both scans. Conclusions Although patient based sensitivity was the same for 64Cu-DOTATATE and 68Ga-DOTATOC in this cohort, more lesions were found by 64Cu-DOTATATE. Furthermore the shelve life of more than 24 hours and a scan window of at least 3 hours make 64Cu-DOTATATE logistically attractive to use in the clinic.

KW - 64Cu-DOTATATE

KW - 68Ga-DOTATOC

KW - Neuroendocrine

KW - Oncology

KW - Endocrine

KW - PET/CT

KW - Neuroendocrine tumors

KW - Somatostatin receptor imaging

U2 - 10.2967/jnumed.116.180430

DO - 10.2967/jnumed.116.180430

M3 - Journal article

VL - 58

SP - 451

EP - 457

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 3

ER -